Tuesday, November 26, 2019

bdenza,bdenza 40mg capsules — myapplepharma

Bdenza is a hormonal therapy, for men who are all affected with prostate carcinoma in metastatic stage. Bdenza 40mg capsules are majorly indicated for prostate carcinoma, which contains Enzalutamide, as an active component considered as non steroidal anti-androgen medication. Bdenza 40mg is involved in association with castration in the therapy of metastatic or long lasting castration resistant prostate cancer. Bdenza 40mg is a prescription medicine, the main ingredient which is used as enzalutamide, only prescribed by medical oncologist.

DOSING CONDITIONS AND ADMINISTRATION

The usual prescribed dosage of Bdenza is 160mg as a single dose by taking with or without food. Bdenza is available in the strength of 40mg; four capsules of Bdenza should be administered at a same time. Bdenza capsule should not crush, not chew taken with glass of water. Dose adjustment: In patients with ≥ grade III toxicity: Bdenza 40mg therapy should be refuse for one week or the symptoms should be reduced to grade II, then restart with same dose or decreased to 80mg or 120mg Strong CYP2C8 inhibitors: While combining with Bdenza capsule, the dosage should be modified by reducing to 80mg as a single dose or avoid this combination. Strong CYP3A4 inducers: Co administration of Bdenza with Strong CYP3A4 inducers, the dosage of Bdenza capsule increased up to 240mg or stop this combination.

PHARMACOKINETICS

Absorption:
After receiving 160mg of Bdenza for mCRPC, from median time to attain peak plasma concentration time at 1 hour (variation with 0.5 to 3 hours). The steady state level of Bdenza is accomplished by day 28 Food does not cause any alteration in absorption of Bdenza capsules.
Distribution:
Volume of distribution 110L High plasma protein bounding capacity of Bdenza capsules is occurs as 97% to 98%
Metabolism:
Two most prominent cytochrome isoenzymes are involved in metabolism of Bdenza capsules; There are two isoenzymes i.e CYP2C8 & CYP3A4; in which CYP2C8 is vital for production of N-desmethyl Enzalutamide which is an active metabolite of Enzalutamide.
Excretion:
Bdenza capsules undergoes excretion by hepatic metabolism Major route of elimination; 71% in urine; 14% in feces The terminal half life period of Bdenza capsules is 5.8 days (range at 2.8 to 10.2 days); N-desmethyl Enzalutamide has half life period of relatively 7.8 to 8.6 days.

MECHANISM

An androgen which is a male hormone is used to develop prostate carcinoma. One of the major hormone secreted by testes and adrenal glands is known as testosterone. Bdenza containing Enzalutamide will interfere with testosterone production, causes tumor cell growth depletion. Bdenza interfere with androgen receptor signaling transduction and leads to cancer cell lysis

DISTINCTLY IN

Pregnancy :
Pregnancy category of Bdenza capsule is D Bdenza is contraindicated to pregnancy; it may cause fetal harm even to death.
Lactation :
Breast feeding is not suggested, Bdenza is contraindicated in lactation.

WARNING AND PRECAUTIONS

During the treatment with Bdenza capsules, patient may suffer with some adverse effects like; Posterior reversible encephalopathy syndrome Seizures In PRES, some neurological disorders occur in patients. The condition can recovered by providing safety measures or discontinue the therapy as soon as possible. PRES is recognized by using MRI In seizures, Before starting the treatment patient must counsel about this adverse reaction and Stop the therapy if possible. Spermatogenesis occurs that may prohibit the male fertility leads to hypo spermatogenesis. In androgen decline the treatment, may have increase exposure of cardiovascular disease like worsening hypertension.

MISSED DOSE

Bdenza 40mg is a chem. Drug, used in prostate cancer. Bdenza capsule should not be self medicated, used by the patients only after getting advice from the medical oncologist. If a single dose missed by patient, then must consult with the physician and follow the instructions as per the guidance of medical adviser, the missed dose should be taken within a time or avoid the missed dose and follow the regular schedule.
For More Information :
Call us : +91–9987711567
Mail to : applepharmaceutical@gmail.com

Monday, November 25, 2019

Trastuzumab - Biceltis 440mg injection online | Myapplepharma


BICELTIS 400MG



DESCRIPTION :

Biceltis is a group of medicines which belongs to anti neoplastic medication. Biceltis is a chemotherapy drug. It is recommended that Biceltis be administered under the guidance of a qualified physician experienced in the use of cancer chemotherapeutic agents.

USES

The injection Biceltis is used alone or combination with other medicine for the treatment in patients who suffering from metastatic breast cancer.
The drug also indicated with combination of other medicine for the treatment of certain types of stomach or esophagus cancer in some persons.

WORK AS

Different type of breast cancer cells has a higher than normal level of a protein called HER2 (human epidermal growth factor receptor 2) on their surface. These HER2 receptors get signals which stimulate the tumor cells to develop and reproduce. But breast cancer cells with too many HER2 receptors can Choice too many growth signals and so start developing and proliferating too much and too fast.
Biceltis acts by adhere itself to the HER2 receptors on the surface of breast cancer cells and stopping them from collecting growth signals. By stopping the signals, Biceltis can slow or inhibit the growth of the breast cancer and the drug is an immune targeted therapy. In addition to inhibiting HER2 receptors, Trastuzumab can also help to fight against breast cancer by attentive the immune system to damage the cancer cells onto which it is attached.

DRUG INTERACTION

In some phenomenal condition, patient should get anthracycline, in that situation patient’s cardiac function should be checked carefully with regular intervals.
Do not take anthracycline treatment for 7 months after stopping the Biceltis treatment.
Biceltis interaction with anthracycline after ending of Biceltis treatment may have a chance of getting cardiac problem. This side effects occur because of Trastuzumab great disaster period is depends on population PK analysis.

CONTRAINDICATION

Probably no contraindicated occurs.
The patients are contraindicated to the component present in the Biceltis, Hence Hypersensitivity reactions are occurring.

STORAGE

Store the drug at 2℃ to 8℃ (refrigerator temperature) Protected the vial away from heat & light Stored at 2℃ to 8℃ for 28 days after reconstitution Stored Biceltis diluted bag at 2℃ to 8℃ for 24 hours.

MISSED DOSE

The drug Missing doses can decrease their usefulness and raises the probability of developing drug resistance, that makes this drug lose their potency. For best results, it is important to accept each scheduled dose of Trastuzumab medication as instructed. If you miss a dose, leave the missed dose and continue with your regular dosing schedule. Do not have two doses to make up for a missed one. If you are not sure about what to do after missing a dose, the take advice with doctor or pharmacist.

For More Information : 

Call us : +91-9987711567
Mail to : applepharmaceutical@gmail.com

Tuesday, November 19, 2019

Apple Infoway

We help you to get high traffic for your websites using latest ethics,visit us

<a href="https://appleinfoway.com/linkedin-marketing.php">Linkedin Marketing company chennai</a>

<a href="https://appleinfoway.com/best-online-management-software.php">Erp software development company in chennai</a>

<a href="https://appleinfoway.com/best-seo-company-chennai.php"> seo company in chennai </a>

<a href="https://appleinfoway.com/wordpress-web-development.php">Wordpress web development company in chennai</a>

<a href="https://appleinfoway.com/crm-development-services.php">CRM software development company in chennai</a>


Saturday, November 16, 2019

soranib tablets ,soranib 200mg - myapplepharma


Description


Soranib belongs to a class of multi kinase inhibitors, the main ingredient which is used as sorafenib. It is not used as curable medicine but Soranib is used to reduce the growth rate of cancer cells by barrier the actions of an aberrant protein signal transduction helps to develop the cancer cells. Soranib is mechanism by depleting the blood supply to the cancer cells and stop their division and production.

DOSAGE

The Soranib Tablets usual dose is 400 mg (2 x 200 mg tablets)
Soranib administrated twice daily on empty stomach (at least 1 hour before or 2 hours after a meal).
• The therapy should continue untill the patient is not clinically benefiting from the treatment.

PHARMACOLOGY

Soranib abolish the surface of cell and intracellular kinase to lag the development of tumor cells. Soranib work as a biological treatment which is a inhibitor of protein kinase which is an enzyme ( chemical messenger). This enzyme enhance grow of tumor cells. Soranib which will also work as multi kinase inhibitor, Since Soranib stops the protein kinase. It has two way actions,
1. Soranib will aim the protein which normally help to develop the malignant cells.
2. Soranib helps to block cancer cells forming from new blood vessels.

PHARMACOKINETICS

Absorption:
Soranib tablet when compared to oral solution the mean bioavailability is 38–49% after absorption. The time to high plasma level of Soranib is 3hrs. Therefore Soranib is administrated without food.
Distribution:
The drug Soranib has human plasma protein bounding is 99.5%
Metabolism:
In liver CYP3A4, Soranib go through metabolism of oxidative and in glucuronidation by UGT1A9. Soranib has totally 8 metabolite are found in which 5 metabolite present in serum.
Elimination:
In oral administration, the total dose excreted 96% within 14 days, and elimination of dose via feces 77% and dose in urine 19% as glucuronidated.

DRUG INTERACTION

Soranib interaction with carbamazepine + dexamethasone + Phenobarbital + phenytoin + rifamipicin leads to reduce in Sorafenib plasma concentration. Soranib interaction with doxorubicin and irinotecan will increase the plasma concentration.

CONTRAINDICATION

The patients is contraindicated to hypersensitivity reaction then avoid using Soranib tablet Carboplatin and paclitaxel interaction with Soranib will cause to squamous cell lung cancer.

LACTATION

It is unknown that this medicine passes into breast milk or could harm a new born baby. Avoid using of Soranib medication, if your breast feeding.

STORAGE

Stored at 25℃ Place in cool and dry place and protect from light and heat. Dispense in its original container and close it tightly. Soranib should keep away from children.

PRECAUTION

To confirm the Using of Soranib medicine is safe for the patient , Inform the doctor if you have any of these other conditions:
• kidney or liver problems other than cancer
• Bleeding(hemophilia)
• high BP
• Cardiac problems
• a history of stroke
• allergies
If you are allergic to Sorafenib (the active ingredients)

SORAFENIB SIDE EFFECTS

Common Sorafenib Side Effects: mouth dryness ; throat soreness ; Tiredness :Acne ; Dry skin ; Nausea ; Itching or rash skin ; Vomiting, ; Diarrhea ; Patchy hair thinning, ; decreased appetite ; Stomach pain ; etc.
Serious Side Effects : Chest heavy feeling ; Sudden weakness ; Increased blood pressure ; Bloody stools ; Coughing up blood / vomit ; fast heart rate ; low concentration ;; dermatology problem; jaundice etc. Mechanism of action: Sorafenib is an oral anti-cancer drugs, and also an inhibitor of various protein kinases, as such as VEGFR, PDGFR and Raf family kinases, because of usage in different kinases it is commonly known for multikinase enzyme inhibitor that decreases cell proliferation in vitro, researchers still made to improve sorafenib mechanism of action to behave as effective inhibitor.
For More Information : 
Call us : +91–9987711567

Thursday, November 7, 2019

HEPCINAT PLUS(索非布韦 & 达卡他韦) - Applepharma.cn

描述

Hepcinat Plus片剂对病毒药物有敌意Hepcinat Plus片剂是单次测量治疗,它是医生开处方药物,只是根据修复专家的信息,他们都在排练 达卡他韦 不是单独使用,为了更好的活动它应该加入 索非布韦 平板电脑。在某些情况下,Hepcinat Plus与利巴韦林联合使用,这是对病毒性药物的一种敌意,用作失代偿(儿童 普格 B或C)肝硬化的一部分

为…规定

Hepcinat Plus的主要标志是;该混合片剂用于治疗由基因型I或III引起的恒定丙型肝炎病毒性疾病。使用Hepcinat Plus片剂时发生的显着限制是减少丙型肝炎基因型I或III污染患者的稳定病毒学反应率。

药理

Hepcinat Plus片剂的活性是通过某种机制引起的;
索非布韦
含有 索非布韦 索非布韦 对肝细胞病毒运动具有敌意,这是一种特异性的药物,通过禁用NS5B RNA依赖的RNA聚合酶蛋白显示其活性;肝炎病毒复制的基础。 索非布韦 被加工成框架尿苷三磷酸盐,这是一种基本的动态代谢产物,它发现了对病毒作用的敌意。在NS5B聚合酶的帮助下,这种动态代谢物混合成肝炎病毒RNA并导致病毒链停止
达卡他韦
含有 达卡他韦 达卡他韦 通过限制病毒生成和病毒粒子收集所需的NS5A蛋白去除对病毒作用的敌意

剂量

Hepcinat Plus片剂含有或不含有食物,在由I或III型基因型引起的慢性丙型肝炎病毒感染的情况下,Hepcinat Plus是单剂量疗法
剂量方案
达卡他韦 通常不单独使用,它与 索非布韦 联合使用Hepcinat Plus的建议剂量是一片应作为单剂量服用如果停用 索非布韦 达卡他韦 也会停止基因型I患者没有肝硬化或代偿性肝硬化:推荐常用剂量的Hepcinat Plus是一片服用单剂量,有或没有食物在失代偿期肝硬化患者中:Hepcinat Plus应与利巴韦林一起作为单剂量服用
基因型III
患者无肝硬化或代偿性肝硬化:建议常用的Hepcinat Plus剂量为一片,单剂量给药,有或没有食物。在失代偿期肝硬化患者中:Hepcinat Plus应与利巴韦林一起服用,每日一次。利巴韦林;患者的血红蛋白水平,剂量可以根据体重计算。 75公斤以下:剂量为1000毫克利巴韦林;对于基因型I或III,建议使用600毫克利巴韦林作为主要剂量,然后以1000毫克 /每小鼠75公斤进行施用:给予失代偿期肝硬化的1200毫克利巴韦林剂量,每日两次。 达卡他韦 的安全性和有效性尚未确定<18年 索非布韦 使用≥12年或重量≥35公斤

药代动力学

吸收
达卡他韦片剂的最大血浆浓度在2小时内发生。达卡他韦的平均生物利用度为67%。索非布韦片剂的最大血浆浓度相对地在0.5至2小时的范围内发生。营养不会使Hepcinat Plus片剂的保留变得多种多样,可以在有或没有营养的情况下服用
分配
达卡他韦 片剂的分布容量为47L 达卡他韦 与人血浆蛋白结合的近99% 索非布韦 的血浆与血浆比率相对为0.7 索非布韦 与人血浆蛋白结合的比例接近61%至65%

代谢
索非布韦 在肝脏中代谢并形成动态代谢产物尿苷三磷酸,在组织蛋白酶A或羧酸酯酶1的帮助下经历代谢,在CYP3A4的辅助下发生 达卡他韦 消化
消除
达卡他韦 的近88%通过粪便排出; 53%为母公司形式;通过尿液排出6.6%。 索非布韦 代谢产物通过尿液排出80%,粪便排出14%,呼出空气排出2.5% 索非布韦 的终末半衰期达到0.51小时; 达卡他韦 半衰期为12至15小时。

副作用

最常见的副作用发生在治疗期间;
头痛,食欲不振,易怒,中性粒细胞减少,贫血,寒战,流感样症状,发热,肌痛,全血细胞减少,疲劳,恶心,腹泻,脂肪酶升高,心脏问题如症状性心动过缓,失眠,瘙痒,虚弱,皮疹,理由是,近99%的药物仅限于人体血浆蛋白质。

注意事项

服用Hepcinat Plus片剂时,使用CYP3A固体诱导剂会导致Hepcinat Plus片剂的治疗反应丧失。远离这一点,以减少不友好的影响Hepcinat Plus导致真正的心动过缓,同时与胺碘酮一起使用,以保持这种情况一些选择性的解决方案给予或结束胺碘酮,如果可以想象。在治疗过程中了解患者心动过缓的情况使用利巴韦特加利巴韦林,由于利巴韦林造成胎儿危害,因此不应在妊娠期使用处方

药物相互影响

虽然使用固体CYP3A诱导剂巩固Hepcinat Plus会导致 达卡他韦 CYP3A固体诱导剂如圣约翰草,利福平,苯妥英或卡马西平的病毒学应答率下降。如果 索非布韦 与P-gp或BCRP抑制剂结合,则会导致 索非布韦 血浆焦点升高。伴有胺碘酮的Hepcinat Plus片剂引起真正的症状性心动过缓。 Hepcinat Plus片剂伴随着对惊厥,抗分枝杆菌或自然物品如圣约翰草的敌意,由于固定Hepcinat Plus和H毫克 CoA还原酶抑制剂而导致减少,这种混合物提示,因为扩大了这些药物(他汀类药物)的表现
药物相互作用的剂量调整
如果同时使用强CYP3A抑制剂, 达卡他韦 的剂量减少至30毫克,同时联合给药同时使用中度CYP3A诱导剂, 达卡他韦 的剂量增加至90毫克同时使用 达卡他韦 与CYP3A强诱导剂应避免,禁忌

禁忌

使用Hepcinat Plus片剂时会出现一些禁忌症在失代偿期肝硬化中,与妊娠期禁忌的利巴韦林联合使用如果患者对Hepcinat Plus中显示的片段有禁忌,则会发生一些过敏反应

怀孕和哺乳期

Hepcinat Plus在怀孕期间使用,被认为是有效的。怀孕类别是B1同时伴有利巴韦林,不建议怀孕怀孕类别:X,导致胎儿伤害不应该建议母乳喂养

失败的剂量

Hepcinat Plus片剂均为单剂量治疗,如果耐受性忽略了这些片剂的测量,必须根据治疗专家给出的指示劝告医生并在时间内进行测量一般错过的测量值应该被跳过并取消标准的剂量计划

药物过量

过量服用Hepcinat Plus片剂是因为错过测量,如果一旦完成剂量发生,必须经常观察患者以支持有害性并给予健康措施血液透析是一种用于从身体取出部分的技术, 索非布韦 通过分区撤离虽然 达卡他韦 是危险的,但系数为54%

存储

Hepcinat Plus的储存条件应分别在室温30℃(86℉)和20℃以及25℃(68℃和77℉)下储存。容器应远离热源,光线和湿气
欲获得更多信息
致电我们 : +919987711567

Saturday, November 2, 2019

revolade 12.5mg- Myapplepharma



revolade 12.5 mg

Revolade 12.5mg is a prescription drug which is used under the supervision of the doctor.
Revolade 12.5mg drug may be used as part of a co-administration therapy. Hence drug may require fortaking it with other medications.

INDICATION

Revolade 12.5mg is mainly indicated for the treatment of patients having :
• lower platelet levels due to chronic immune thrombocytopenia
• lower platelet counts due to chronic hepatitis C virus infection
• Severe aplastic Anemia :
• First line treatment of severe aplastic Anemia
• Treatment of refractory severe aplastic Anemia

DOSAGE

Chronic Immune Thrombocytopenia
The recommended dose of Revolade has Initial: 50 mg PO qDay Adjust dose to achieve Control platelet count (Plt) >50 x 10^9/L to reduces risk of bleeding; not to exceed 75 mg/day

Chronic Hepatitis C-associated Thrombocytopenia
The recommended dose of Revolade has Initial: 25 mg PO qDay Dose is Adjust in 25 mg accretion q2weeks PRN to attain target Plt needed to start/control antiviral therapy with pegylated interferon and ribavirin; not to exceed 100 mg/day During antiviral therapy, regulate dose to stop dose reductions of peginterferon Severe Aplastic Anemia
First-line therapy: Concomitant use with standard immunosuppressive therapy, for patients with serious aplastic Anemia (SAA) The recommended dose of Revolade: 150 mg PO qDay for 6 months Do not give more than starting dose; total duration is 6 months

Refractory SAA
The drug given for this condition who fail to respond enough to at least 1 before immunosuppressive therapy The recommended dose of Revolade: 50 mg PO qDay Adjust dose in 50-mg accretion q2Weeks PRN to attain target Plt ≥50 x 10^9/L as required; not exceed 150 mg/day; may take up to 16 weeks for hematologic response.

MECHANISM

Eltrombopag belongs to growth factors which excite platelet production through the thrombopoietin (TPO) receptor. Eltrombopag is a thrombopoietin nonpeptide agonist which have high platelet counts by binding to and activating the TPO receptor. It stimulates pathways within the cell to raises the production and development of marrow progenitor (parent) cells to strengthen platelet production.

ADME

Absorption:
peak plasma concentration is 2-6 hours
Distribution:
highly human plasma protein bounding is >99% and in blood plasma level is 50% to 79%
Metabolism:
predominantly metabolised through cleavage, oxidation and conjugation with glucuronic acid.
Elimination:
Revolade 12.5mg eliminated primarily via feces 59%, along with 31% via renally excreted
Half-life of Revolade 12.5mg healthy patients is 21-23 hours and idiopathic thrombocytopenic purpura is 26-35 hours.

PRECAUTION

The drug causes warning condition call the doctor while new medication interaction If other blood clot risk factors, then avoid the drug because it will high level of platelet counts and blood clots.
If the patients have cataracts, avoid the drug due to the drug effects cataracts and make the condition worse.
Disease progression warning: Avoid using the drug while the patients have myelodysplastic syndrome (MDS), will increases the risk of death.

DRUG INTERACTION

• Revolade 12.5mg co administration with these drugs ezetimibe, glyburide, Olmesartan, repaglinide, valsartan, imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, Bosentan, sulfasalazine, and topotecan irinotecan leads increase of side effects. hence the doctor may reduce your dosage of these drugs if required.
• Revolade 12.5mg concomitant use with Cholesterol-reducing drugs like atorvastatin, fluvastatin, rosuvastatin, pravastatin, and simvastatin, pitavastatin. Have high side effects can contains muscle pain. The doctor may decrease the dosage of your cholesterol drugs.
• Revolade 12.5mg combination with Antacids, vitamins, or supplements which involves Ca, Al, Fe, Se, Zn, or Mg. To stop interactions, then take Revolade two hours before or four hours after administrating any of these products.
For More Information
Call us :  +91-9987711567
Mail to : applepharmaceutical@gmail.com

Friday, November 1, 2019

Купить Bdenza | Bdenza цена лекарства - applepharma.su

ОПИСАНИЕ

Bdenza — это гормональная терапия, для мужчин, у которых все поражены раком простаты в метастатической стадии.
Капсулы Bdenza 40mg в основном показаны для рака предстательной железы, который содержит Enzalutamide, в качестве активного компонента, рассматриваемого как не
стероидные антиандрогенные препараты. Bdenza 40mg участвует в кастрации при метастатической или длительной терапии
устойчивый к кастрации рак простаты. Bdenza 40mg является рецептурным лекарством, основным ингредиентом которого является
используется как энзалутамид, только по назначению медицинского онколога.

УСЛОВИЯ ДОЗИРОВАНИЯ И АДМИНИСТРАЦИЯ

Обычная предписанная доза Bdenza составляет 160 мг как одна доза, принимая с пищей или без.
 Bdenza доступен в силе 40mg; четыре капсулы Bdenza следует вводить одновременно.
 Капсулы бденцы не следует раздавливать, не разжевывать, запивая стаканом воды.
 Коррекция дозы: у пациентов с ≥ III степенью токсичности: следует отказаться от терапии Бдензой 40mg в течение одной недели или уменьшить симптомы до II степени.
 затем перезапустите с той же дозой или уменьшите до 80 мг или 120 мг. Сильные ингибиторы CYP2C8: при комбинировании с капсулой Bdenza дозировка должна быть изменена
 снижение до 80 мг в виде разовой дозы или избегать этой комбинации. Сильные индукторы CYP3A4: совместное введение Bdenza с сильными индукторами CYP3A4,
 Доза капсулы Bdenza увеличилась до 240mg или прекратить эту комбинацию.

Фармакокинетика

Поглощение:
После получения 160 мг Bdenza для mCRPC, от среднего времени до достижения пиковой концентрации в плазме через 1 час (изменение от 0,5 до 3 часов).
К 28-му дню достигается устойчивый уровень бденцы. Пища не вызывает каких-либо изменений в абсорбции капсул бденз.
Распределение:
Объем распределения 110л Высокая концентрация белков плазмы в капсулах Bdenza составляет от 97% до 98%.
Метаболизм:
Два наиболее известных изофермента цитохрома участвуют в метаболизме капсул Bdenza; Существует два изофермента, т.е. CYP2C8 и CYP3A4;
в котором CYP2C8 жизненно важен для производства N-десметил-энзалутамида, который является активным метаболитом энзалутамида.
Выведение:
Капсулы Bdenza подвергаются экскреции в результате метаболизма в печени. Основной путь выведения; 71% в моче; 14% в кале Терминал
период полураспада капсул Bdenza составляет 5,8 дня (диапазон от 2,8 до 10,2 дня); N-десметил энзалутамид имеет период полураспада относительно 7,8–8,6 дней.

МЕХАНИЗМ

Андроген, который является мужским гормоном, используется для развития рака предстательной железы. Один из основных секретируемых гормонов
 яичками и надпочечниками известен как тестостерон. Bdenza, содержащий Enzalutamide будет мешать выработке тестостерона,
 вызывает истощение опухолевых клеток. Bdenza вмешивается в передачу сигнала рецептора андрогена и приводит к лизису раковых клеток

ОТЛИЧНО В

Беременность
Категория беременности по Бдензе-капсуле — Бдензе противопоказана к беременности; это может причинить вред плоду даже до смерти.
Лактация :
Грудное вскармливание не рекомендуется, Бдензе противопоказан при лактации.

Пропущенная доза

Bdenza 40mg является химией. Препарат, применяемый при раке предстательной железы. Капсула Bdenza не должна быть самолечена, используется только пациентами
после получения консультации от медицинского онколога. Если пациент пропустил одну дозу, то должен проконсультироваться с врачом и следовать
 инструкции в соответствии с указаниями медицинского консультанта, пропущенную дозу следует принимать в течение определенного периода времени или избегать пропущенной дозы и
 следуйте обычному графику.

ПРОТИВОПОКАЗАНИЯ

Капсулы Bdenza противопоказаны к состоянию беременности, что может привести к повреждению плода и к смерти. Анафилактическая реакция происходит,
Если пациент противопоказан ингредиент, присутствующий в капсулах Bdenza.
Для дополнительной информации
позвоните нам : 8(800)5517717
почта для: info@applepharma.su